Prognostic factors of survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: Sequencing might matter.
Antoine Angelergues
No relevant relationships to disclose
Denis Maillet
No relevant relationships to disclose
Aude Flechon
Honoraria - Sanofi
Mustafa Ozguroglu
No relevant relationships to disclose
Florence Mercier
Consultant or Advisory Role - Boston Scientific; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Sanofi
Aline Guillot
No relevant relationships to disclose
Sylvestre Le Moulec
No relevant relationships to disclose
Gwenaelle Gravis
Consultant or Advisory Role - Sanofi (U)
Philippe Beuzeboc
Honoraria - Sanofi
Christophe Massard
No relevant relationships to disclose
Thibault De La Motte Rouge
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Astellas Pharma; Millennium
Reza-Thierry Elaidi
No relevant relationships to disclose
Stephane Oudard
Consultant or Advisory Role - Amgen; Bayer; Keocyt; Novartis; Roche; Sanofi
Honoraria - Amgen; Bayer; Keocyt; Novartis; Pfizer; Roche; Sanofi